Pancreatic cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Cascinu, S ^a   Falconi, M ^b   Valentini, V ^c   Jelic, S ^d  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CA 19-9 ANTIGEN; CAPECITABINE; CETUXIMAB; CISPLATIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MORPHINE; OPIATE DERIVATIVE; OXALIPLATIN; PLATINUM COMPLEX;

ACINAR CELL CARCINOMA; ADJUVANT THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NERVE BLOCK; NERVE PLEXUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PAIN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS SURGERY; PANCREATICODUODENECTOMY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT PLANNING; TREATMENT RESPONSE;

CHEMOTHERAPY, ADJUVANT; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; NEOPLASM STAGING; PALLIATIVE CARE; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77954344963     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq165     Document Type: Article

References (27)

1. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-592.
2. Verdecchia A, Francisci S, Brenner H et al. Recent cancer survival in Europe: a 2000-2 period analysis. Lancet Oncol 2007; 8: 784-796.
3. Brand RE, Lerch MM, Rubinstein WS et al. Participants of the Fourth International Symposium of Inherited Diseases of the Pancreas. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007; 56: 1460-1469.
4. Rulyak SJ, Kimmey MB, Veenstra DL, Brentnall TA. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc 2003; 57: 23-29.
5. Canto MI. Screening and surveillance approaches in familial pancreatic cancer. Gastrointest Endosc Clin N Am 2008; 18: 535-553.
6. Brune K, Abe T, Canto M et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol 2006; 30: 1067-1076.
7. Tamm EP, Balachandran A, Bhosale P et al. Update on 3D and multiplanar MDCT in the assessment of biliary and pancreatic pathology. Abdom Imaging 2009; 34: 64-74.
8. Chang L, Stefanidis D, Richardson WS et al. The role of staging laparoscopy for intraabdominal cancers: an evidence-based review. Surg Endosc 2009; 23: 231-241.
9. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210.
10. Oettle H, Post S, Neuhaus P, Gellert K et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277.
11. Neoptolemos JP, Buchler M, Stocken DD. ESPAC-3(v2): a multicenter, international, openlabel, randomised controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5FU/FA) versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol 2009; 27 (Suppl): 203.
12. Khanna A, Walker GR, Livingstone AS et al. Is adjuvant 5-FU based chemoradiotherapy for resectable pancreatic adenocarcinoma beneficial? A meta-analysis of an unanswered question. J Gastrointest Surg 2006; 10: 689-697.
13. Regine W, Winter KA, Abrams R et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008; 299: 1019-1026.
14. Stocken DD, Buchler MW, Dervenis C et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005; 92: 1372-1381.
15. Evans DB, Varadhachary GR, Crane CH et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 2: 3496-3502.
16. Varadhachary GR, Wolff RA, Crane CH et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26: 3487-3495.
17. Valentini V, Calvo F, Reni M et al. Intra-operative radiotherapy (IORT) in pancreatic cancer: joint analysis of the ISIORT-Europe experience. Radiother Oncol 2009; 91: 54-59.
18. Katz MH, Pisters PW, Evans DB et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008; 206: 833-846.
19. Chauffert B, Mornex F, Bonnetain F et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008; 19: 1592-1599.
20. Loherer PJ, Powell ME, Cardenes HR et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol 2008; 26 (Suppl): 4506.
21. Huguet F, Girard N, Seblain-El Guerche C et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 2009; 27: 2269-2277.
22. Verslype C, Van Cutsem E, Dicato M et al. The management of pancreatic cancer. Current 8th expert opinion and recommendations derived from the World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol 2007; 18 (Suppl): 1-10.
23. Heinemann V, Boeck S, Hinke A et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC 2008; 28: 8-82.
24. Colucci G, Labianca R, Di Costanzo F et al. A randomised trial of gemcitabine versus gemcitabine plus cisplatin in chemotherapy-nai{dotless}̈ve advanced pancreatic adenocarcinoma: The GIP-1 study. J Clin Oncol 2009; 27 (Suppl): 4504.
25. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
26. Riess H, Pelzer U, Stieler J et al. A randomised second line trial in patients with gemcitabine refractory advanced pancreatic cancer- CONKO 003. J Clin Oncol 2007; 25 (Suppl): 201.
27. Huser N, Michalski CW, Schuster T et al. Systematic review and meta-analysis of prophylactic gastroenterostomy for unresectable advanced pancreatic cancer. Br J Surg 2009; 96: 711-719.